 Michelle Barron
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 9 | 2026 | 529 | 1.400 |
Why?
| | Influenza, Human | 9 | 2026 | 616 | 1.060 |
Why?
| | Hospitalization | 21 | 2026 | 2433 | 0.820 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1054 | 0.670 |
Why?
| | Ambulatory Care | 7 | 2025 | 600 | 0.670 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 334 | 0.650 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2025 | 157 | 0.590 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 81 | 0.520 |
Why?
| | Emergency Service, Hospital | 14 | 2025 | 2310 | 0.520 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 70 | 0.480 |
Why?
| | Vaccines, Attenuated | 1 | 2016 | 129 | 0.470 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2025 | 428 | 0.470 |
Why?
| | Viremia | 2 | 2009 | 158 | 0.460 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 38 | 0.440 |
Why?
| | Adult | 43 | 2026 | 40449 | 0.430 |
Why?
| | Staphylococcal Infections | 6 | 2020 | 388 | 0.400 |
Why?
| | Antifungal Agents | 9 | 2020 | 149 | 0.380 |
Why?
| | Middle Aged | 36 | 2026 | 35875 | 0.380 |
Why?
| | Antibodies, Viral | 1 | 2016 | 672 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2009 | 675 | 0.350 |
Why?
| | Dendritic Cells | 2 | 2006 | 499 | 0.330 |
Why?
| | Aged | 28 | 2026 | 25913 | 0.320 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 455 | 0.320 |
Why?
| | Serotonin Syndrome | 1 | 2010 | 4 | 0.310 |
Why?
| | Oxazolidinones | 1 | 2010 | 17 | 0.310 |
Why?
| | Bacteremia | 3 | 2020 | 221 | 0.310 |
Why?
| | Immunization, Secondary | 4 | 2022 | 91 | 0.310 |
Why?
| | Acetamides | 1 | 2010 | 37 | 0.300 |
Why?
| | Humans | 63 | 2026 | 144759 | 0.300 |
Why?
| | Influenza A Virus, H3N2 Subtype | 2 | 2026 | 50 | 0.290 |
Why?
| | Methicillin | 1 | 2009 | 10 | 0.290 |
Why?
| | Case-Control Studies | 11 | 2026 | 3604 | 0.290 |
Why?
| | Adaptive Immunity | 1 | 2009 | 169 | 0.280 |
Why?
| | United States | 20 | 2026 | 15966 | 0.280 |
Why?
| | HIV-1 | 2 | 2006 | 896 | 0.280 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2020 | 248 | 0.270 |
Why?
| | Platelet Transfusion | 1 | 2009 | 80 | 0.270 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 206 | 0.270 |
Why?
| | Female | 38 | 2026 | 78271 | 0.270 |
Why?
| | Adolescent | 21 | 2026 | 22428 | 0.260 |
Why?
| | Male | 35 | 2026 | 72315 | 0.260 |
Why?
| | Immunocompromised Host | 4 | 2024 | 201 | 0.250 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 242 | 0.250 |
Why?
| | Vitamin K Deficiency | 1 | 2006 | 9 | 0.240 |
Why?
| | AIDS Vaccines | 1 | 2006 | 52 | 0.240 |
Why?
| | Vaccination | 8 | 2026 | 1423 | 0.230 |
Why?
| | Rhizopus | 1 | 2005 | 4 | 0.230 |
Why?
| | Facial Pain | 1 | 2005 | 12 | 0.230 |
Why?
| | Mucormycosis | 1 | 2005 | 19 | 0.220 |
Why?
| | Blood Platelets | 1 | 2009 | 400 | 0.220 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 138 | 0.220 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 294 | 0.210 |
Why?
| | Young Adult | 16 | 2026 | 14105 | 0.210 |
Why?
| | Cross Infection | 3 | 2014 | 262 | 0.210 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 39 | 0.210 |
Why?
| | Klebsiella Infections | 2 | 2014 | 26 | 0.210 |
Why?
| | Carbapenems | 2 | 2014 | 26 | 0.210 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.210 |
Why?
| | Klebsiella pneumoniae | 2 | 2014 | 47 | 0.210 |
Why?
| | beta-Lactamases | 2 | 2014 | 51 | 0.200 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 415 | 0.200 |
Why?
| | Immunity, Innate | 1 | 2009 | 846 | 0.200 |
Why?
| | Petroleum | 1 | 2023 | 10 | 0.200 |
Why?
| | Petroleum Pollution | 1 | 2023 | 10 | 0.200 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2024 | 131 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 136 | 0.190 |
Why?
| | Mycoses | 1 | 2003 | 88 | 0.190 |
Why?
| | Candidiasis, Invasive | 2 | 2014 | 6 | 0.190 |
Why?
| | Sputum | 1 | 2024 | 308 | 0.180 |
Why?
| | Brain Diseases | 1 | 2003 | 152 | 0.180 |
Why?
| | Sinusitis | 1 | 2005 | 228 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2023 | 107 | 0.180 |
Why?
| | Aged, 80 and over | 10 | 2025 | 8265 | 0.170 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 579 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 235 | 0.170 |
Why?
| | Tuberculosis | 1 | 2024 | 291 | 0.160 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.160 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 21 | 0.160 |
Why?
| | Cryptococcosis | 1 | 2020 | 31 | 0.160 |
Why?
| | Zygomycosis | 2 | 2009 | 6 | 0.150 |
Why?
| | Lung Transplantation | 2 | 2013 | 338 | 0.150 |
Why?
| | Water Pollutants, Chemical | 1 | 2023 | 234 | 0.150 |
Why?
| | Organ Transplantation | 3 | 2020 | 247 | 0.150 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.140 |
Why?
| | Seasons | 3 | 2026 | 556 | 0.140 |
Why?
| | Intensive Care Units | 5 | 2021 | 916 | 0.140 |
Why?
| | Cefazolin | 1 | 2018 | 22 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2024 | 17066 | 0.140 |
Why?
| | RNA, Messenger | 5 | 2024 | 2832 | 0.140 |
Why?
| | Pneumonia | 1 | 2024 | 631 | 0.140 |
Why?
| | Child, Preschool | 8 | 2026 | 11787 | 0.130 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2016 | 38 | 0.120 |
Why?
| | Disease Outbreaks | 3 | 2015 | 422 | 0.120 |
Why?
| | Echinocandins | 2 | 2014 | 8 | 0.120 |
Why?
| | Influenza B virus | 2 | 2026 | 47 | 0.120 |
Why?
| | North America | 1 | 2016 | 310 | 0.110 |
Why?
| | Spores, Bacterial | 1 | 2015 | 19 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 28 | 0.110 |
Why?
| | Containment of Biohazards | 1 | 2015 | 21 | 0.110 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 20 | 0.110 |
Why?
| | Anti-Bacterial Agents | 4 | 2020 | 1907 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1168 | 0.110 |
Why?
| | Infant | 6 | 2026 | 10034 | 0.110 |
Why?
| | Child | 9 | 2026 | 22633 | 0.110 |
Why?
| | Population Surveillance | 2 | 2015 | 485 | 0.110 |
Why?
| | Coinfection | 1 | 2016 | 141 | 0.110 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 100 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 3 | 2020 | 370 | 0.100 |
Why?
| | Bacterial Infections | 1 | 2016 | 246 | 0.100 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 4 | 0.100 |
Why?
| | Treatment Outcome | 9 | 2020 | 11679 | 0.100 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 20 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2020 | 736 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 216 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2015 | 254 | 0.100 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 340 | 0.100 |
Why?
| | Vaccines, Combined | 2 | 2023 | 49 | 0.100 |
Why?
| | Invasive Pulmonary Aspergillosis | 1 | 2013 | 7 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 33 | 0.100 |
Why?
| | Daptomycin | 1 | 2013 | 18 | 0.100 |
Why?
| | Creatine Kinase | 1 | 2013 | 72 | 0.090 |
Why?
| | Rectum | 1 | 2014 | 180 | 0.090 |
Why?
| | Drug Interactions | 2 | 2013 | 398 | 0.090 |
Why?
| | Muscular Diseases | 1 | 2013 | 108 | 0.090 |
Why?
| | Risk Factors | 8 | 2024 | 10779 | 0.090 |
Why?
| | Critical Care | 2 | 2016 | 695 | 0.090 |
Why?
| | Antiviral Agents | 3 | 2026 | 767 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 401 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.080 |
Why?
| | Chemoprevention | 1 | 2011 | 90 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 540 | 0.080 |
Why?
| | Sertraline | 1 | 2010 | 27 | 0.080 |
Why?
| | Linezolid | 1 | 2010 | 25 | 0.080 |
Why?
| | Citalopram | 1 | 2010 | 32 | 0.080 |
Why?
| | Lung Diseases, Fungal | 1 | 2009 | 13 | 0.080 |
Why?
| | Tremor | 1 | 2010 | 98 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 439 | 0.070 |
Why?
| | Hospital Mortality | 2 | 2023 | 1030 | 0.070 |
Why?
| | Pregnancy | 3 | 2025 | 7190 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 865 | 0.060 |
Why?
| | Newspapers as Topic | 1 | 2006 | 8 | 0.060 |
Why?
| | Professional Misconduct | 1 | 2006 | 13 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2024 | 824 | 0.060 |
Why?
| | Ethics, Research | 1 | 2006 | 32 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 51 | 0.060 |
Why?
| | Hemorrhagic Disorders | 1 | 2006 | 10 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 28 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 467 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 38 | 0.060 |
Why?
| | Drug Antagonism | 1 | 2006 | 9 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2006 | 1982 | 0.060 |
Why?
| | Phenytoin | 1 | 2006 | 21 | 0.060 |
Why?
| | Prothrombin Time | 1 | 2006 | 33 | 0.060 |
Why?
| | Vitamin K | 1 | 2006 | 45 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 132 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 37 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 205 | 0.060 |
Why?
| | Thrombolytic Therapy | 1 | 2006 | 163 | 0.050 |
Why?
| | Immunity, Herd | 1 | 2024 | 7 | 0.050 |
Why?
| | Pain | 1 | 2010 | 779 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 1 | 2006 | 244 | 0.050 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2024 | 81 | 0.050 |
Why?
| | Autopsy | 1 | 2003 | 94 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2006 | 235 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2006 | 291 | 0.050 |
Why?
| | Spermine | 1 | 2023 | 29 | 0.050 |
Why?
| | Oils | 1 | 2023 | 22 | 0.050 |
Why?
| | Hydrocarbons | 1 | 2023 | 31 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
| | Liposomes | 1 | 2005 | 250 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 171 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 307 | 0.050 |
Why?
| | Time Factors | 4 | 2022 | 7173 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 60 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2006 | 358 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 91 | 0.050 |
Why?
| | Advisory Committees | 1 | 2024 | 228 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 7990 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2006 | 1126 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 90 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2002 | 220 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2023 | 103 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2002 | 322 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1382 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 278 | 0.040 |
Why?
| | Lipopeptides | 2 | 2014 | 16 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 23 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 187 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 496 | 0.040 |
Why?
| | Water | 1 | 2023 | 469 | 0.040 |
Why?
| | Hospitals | 2 | 2015 | 730 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 555 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2015 | 2029 | 0.040 |
Why?
| | Vancomycin | 1 | 2020 | 93 | 0.040 |
Why?
| | RNA, Viral | 1 | 2002 | 688 | 0.040 |
Why?
| | Prevalence | 1 | 2006 | 2834 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2018 | 15 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2496 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4154 | 0.030 |
Why?
| | Cytokines | 1 | 2006 | 2061 | 0.030 |
Why?
| | Incidence | 2 | 2016 | 2879 | 0.030 |
Why?
| | Endocarditis | 1 | 2018 | 39 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 652 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 758 | 0.030 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2015 | 26 | 0.030 |
Why?
| | Contraindications | 1 | 2015 | 91 | 0.030 |
Why?
| | Developed Countries | 1 | 2015 | 38 | 0.030 |
Why?
| | Patient Isolation | 1 | 2015 | 20 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2002 | 2947 | 0.030 |
Why?
| | Africa | 1 | 2015 | 116 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 70 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2015 | 71 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 403 | 0.030 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2015 | 42 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 96 | 0.030 |
Why?
| | Ebolavirus | 1 | 2015 | 89 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 192 | 0.030 |
Why?
| | Travel | 1 | 2015 | 136 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 6429 | 0.030 |
Why?
| | Colorado | 2 | 2014 | 4564 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 119 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 333 | 0.020 |
Why?
| | Rosuvastatin Calcium | 1 | 2013 | 21 | 0.020 |
Why?
| | Fluorobenzenes | 1 | 2013 | 17 | 0.020 |
Why?
| | Allografts | 1 | 2013 | 150 | 0.020 |
Why?
| | Simvastatin | 1 | 2013 | 60 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2014 | 196 | 0.020 |
Why?
| | Muscular Dystrophies | 1 | 1992 | 30 | 0.020 |
Why?
| | Dystrophin | 1 | 1992 | 39 | 0.020 |
Why?
| | Feces | 1 | 2015 | 513 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1135 | 0.020 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2014 | 246 | 0.020 |
Why?
| | APACHE | 1 | 2011 | 66 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1489 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1539 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1658 | 0.020 |
Why?
| | Risk | 1 | 2013 | 911 | 0.020 |
Why?
| | Neoplasms | 1 | 2006 | 2875 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2117 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 708 | 0.020 |
Why?
| | Anticoagulants | 1 | 2015 | 722 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 689 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 532 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 73 | 0.020 |
Why?
| | Sulfonamides | 1 | 2013 | 580 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2015 | 947 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 342 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1560 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 174 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2009 | 2919 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 76 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2006 | 18 | 0.020 |
Why?
| | Echo-Planar Imaging | 1 | 2006 | 23 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 41 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2006 | 88 | 0.020 |
Why?
| | Convalescence | 1 | 2006 | 19 | 0.020 |
Why?
| | Mass Screening | 1 | 2015 | 1347 | 0.010 |
Why?
| | Drug Approval | 1 | 2006 | 89 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1053 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2006 | 316 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 405 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 275 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 846 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 851 | 0.010 |
Why?
| | Risk Assessment | 1 | 2013 | 3671 | 0.010 |
Why?
| | Research | 1 | 2006 | 431 | 0.010 |
Why?
| | Patient Selection | 1 | 2006 | 719 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4109 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5960 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2006 | 2925 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2006 | 5408 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 4271 | 0.010 |
Why?
| | Brain | 1 | 2006 | 2933 | 0.010 |
Why?
| | DNA Probes | 1 | 1992 | 59 | 0.010 |
Why?
| | X Chromosome | 1 | 1992 | 67 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1992 | 42 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1992 | 124 | 0.010 |
Why?
| | Sex Chromosome Aberrations | 1 | 1992 | 69 | 0.010 |
Why?
| | Muscles | 1 | 1992 | 333 | 0.010 |
Why?
| | Exons | 1 | 1992 | 358 | 0.010 |
Why?
| | Blotting, Western | 1 | 1992 | 1187 | 0.000 |
Why?
| | Biopsy | 1 | 1992 | 1075 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1519 | 0.000 |
Why?
|
|
Barron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|